Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

About this update from Hemostemix Inc

[{"type":"text","content":"Hemostemix to Attend DFCon San Antonio and Closed its Private PlacementCalgary, Alberta--(Newsfile Corp. - December 2, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to announce its participation in DFCon 2025, hosted by the American Limb Preservation Society in San Antonio, Texas - the global epicentre for innovation in diabetic foot care, vascular medicine, and limb preservation. With more than 500 delegates expected, DFCon gathers the widest spectrum of professionals shaping the future of diabetic limb salvage: podiatrists, vascular surgeons, wound-care experts, infectious disease specialists, endocrinologists/diabetologists, cardiovascular and endovascular specialists, nurses, NPs, PAs, residents, fellows, physical therapists, and industry innovators.\"VesCell saves diabetic limbs from amputation, and that saves lives,\" stated Thomas Smeenk CEO. DFCon remains the world's leading interdisciplinary diabetic foot conference, and we are delighted to be a solution-based participant. Here is why: as compared to a 50% mortality rate within five years for no option patients, the University of Toronto published our treatment generated 0% mortality and limb preservation in 83% of subjects followed for 4.5 years as a midpoint result in our phase II clinical trial! Unblinded the 83% received VesCell. As published, looking at only the patients who presented with wound ulcers before administration of ACP-01, (21 treatment, 8 placebo), Ulcer size in the treated group decreased from a mean of 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months (wounds decreased from the size of a wild strawberry to the size of a grain of sand). There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment. The treatment group had one amputation (4.8%) and one death (4.8%); the placebo group had 2 amputations (25%) and 1 death (12.5%),\" and that story needs to be told,\" Smeenk said.Across three high-intensity days - Friday, Saturday, and Sunday - Hemostemix will meet with clinicians, researchers, and innovators to highlight the significant outcomes following treatment with ACP-01 (VesCell™), for vascular and ischemic conditions that underpin chronic wounds and diabetic limb-threatening ischemia.Financing The TSXV has approved a non brokered pri...

More updates from Hemostemix Inc